CORDIS
EU research results

CORDIS

English EN

New medicines for tuberculosis

Objective

The explicit aim of the NM4TB project is to successfully develop new drugs for the treatment of tuberculosis (TB) with the following desired properties: * High potency to reduce treatment duration, * Activity against persistent bacilli, * Inhibition of ne w target classes, * Activity against multidrug resistant TB, * Specificity for Mycobacterium tuberculosis. This will be achieved through an integrated approach implemented by a team that combines some of Europe's leading academic TB researchers with a maj or pharmaceutical company and three SMEs with a strong commitment to discovering new anti-infective agents. Four interlinked, cutting-edge work packages (WP1) have been assembled: * WP1 provides all of the enabling technologies expected of a modern drug development programme, * WP2 is devoted to validation of an attractive range of targets, * WP3 generates three dimensional structures of targets with their inhibitors, * WP4 provides an exhaustive approach to screening and lead optimization culminating in candidate drugs. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas su ch as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two as-yet untouched areas of the physiology of M. tuberculosis signal transduction pathways and persistence.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE

Address

Batiment Ce 3.316 Station 1
Lausanne

Switzerland

Administrative Contact

Stewart T. COLE (Professor)

Participants (21)

Sort alphabetically

Expand all

UPPSALA UNIVERSITET

Sweden

ASTRAZENECA

United Kingdom

QUEEN MARY & WESTFIELD COLLEGE

United Kingdom

INSTITUT PASTEUR

France

UNIVERSITÀ DEGLI STUDI DI PAVIA

Italy

STATENS SERUM INSTITUT

Denmark

LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.HANS-KNÖLL-INSTITUT

Germany

UNIVERSITY OF MANCHESTER

United Kingdom

COMENIUS UNIVERSITY, FACULTY OF NATURAL SCIENCES

Slovakia

UNIVERSITY OF ZURICH

Switzerland

VICHEM CHEMIE RESEARCH LTD.

Hungary

ASTEX THERAPEUTICS LIMITED

United Kingdom

NEED PHARMACEUTICALS

Italy

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

A.N. BAKH INSTITUTE OF BIOCHEMISTRY OF THE RUSSIAN ACADEMY OF SCIENCES

Russia

COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH

South Africa

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

ASTRA ZENECA INDIA PVT LTD

India

UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA

Spain

SCIPROM SARL

Switzerland

Project information

Grant agreement ID: 18923

  • Start date

    1 January 2006

  • End date

    30 June 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 12 879 968

  • EU contribution

    € 11 070 000

Coordinated by:

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE

Switzerland